Recommendations include screening for and addressing adverse social determinants of health
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression
2010 to 2023 Saw Increase in GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity